Anti-CD20 Therapies Show Similar Safety, Efficacy in RRMS

Anti-CD20 Therapies Show Similar Safety, Efficacy in RRMS

306623

Anti-CD20 Therapies Show Similar Safety, Efficacy in RRMS

Anti-CD20 antibody therapies that target B-cells are highly effective for reducing the risk of relapses in people with relapsing-remitting multiple sclerosis (RRMS), a new analysis confirms. The analysis did not find any significant differences in efficacy or safety among the anti-CD20 therapies currently approved to treat RRMS, though its researchers noted a need for more long-term studies to evaluate these medicines’ safety profiles. The results were published in IBRO Neuroscience Reports, in a paper titled “The…

You must be logged in to read/download the full post.